Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RECQL | P46063 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 4/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6940505 | 0.88 | ALDH1A1 (0.50) | RECQLTSHRHPGDALDH1A1MEN1 | |
| SCHEMBL14984044 | 0.86 | FAAH (0.48) | RECQLTSHRHPGDALDH1A1MEN1 | |
| SCHEMBL16669295 | 0.81 | FAAH (0.59) | MEN1KMT2AMAPTASAH1 | |
| SCHEMBL1897281 | 0.81 | ALDH1A1 (0.48) | RECQLTSHRHPGDALDH1A1MEN1 | |
| SCHEMBL7745307 | 0.81 | ALDH1A1 (0.48) | RECQLTSHRHPGDALDH1A1MEN1 | |
| SCHEMBL6470541 | 0.81 | ALDH1A1 (0.48) | RECQLTSHRHPGDALDH1A1MEN1 | |
| SCHEMBL5196145 | 0.80 | MGAM (0.41) | RECQLTSHRHPGDALDH1A1MEN1 | |
| SCHEMBL15903262 | 0.80 | ALDH1A1 (0.54) | HPGDALDH1A1ASAH1 | |
| SCHEMBL1498601 | 0.79 | FAAH (0.62) | MEN1KMT2AMAPTASAH1 | |
| SCHEMBL11513011 | 0.79 | FAAH (0.62) | MEN1KMT2AMAPTASAH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11713312-B2 | Substituted bicyclic compounds as farnesoid X receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-08-01 | — | — | US | disclosed |
| US-20220135550-A1 | SUBSTITUTED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2022-05-05 | — | — | US | disclosed |
| US-11254663-B2 | Substituted bicyclic compounds as farnesoid X receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220135550-A1 | SUBSTITUTED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | FXR1, NR1H4, FXR2 | RECQL 4433/4885TSHR 798/4885HPGD 962/4885 |
| US-11254663-B2 | Substituted bicyclic compounds as farnesoid X receptor modulators | FXR1, NR1H4, FXR2 | RECQL 4433/4885TSHR 798/4885HPGD 962/4885 |
| US-11713312-B2 | Substituted bicyclic compounds as farnesoid X receptor modulators | FXR1, NR1H4, FXR2 | RECQL 4433/4885TSHR 798/4885HPGD 962/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.